Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Becton, Dickinson Banks On Bard Buyout, Medical Unit Weak

Published 12/13/2017, 08:11 PM
Updated 07/09/2023, 06:31 AM

On Dec 13, 2017, we issued an updated research report on, Becton, Dickinson and Company (NYSE:BDX) , popularly known as BD. The stock carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The leading MedTech company is steadily progressing with the acquisition of C. R. Bard (NYSE:BCR) . Post completion, BD expects growth in adjusted earnings starting fiscal 2019. The acquisition will enable the company generate profits from complementary businesses and geographical expansion.

On Nov 16, BD announced that it will divest soft tissue core needle biopsy products for $100M to Merit Medical Systems Inc. (NASDAQ:MMSI) . The products are currently sold under Bard's Aspira product line of tunneled home drainage catheters and accessories. The divestment is contingent on the completion of the BD’s acquisition of Bard.

Year to date, BD has outperformed the industry in terms of stock price. The company has returned 34.2%, comparing favorably with the industry’s rally of just 21.3%. Notably, the current return is relatively higher than the S&P 500’s increase of 21.9%.

On the flip side, lackluster performance by BD’s Medical Unit is a concern. Performance in the segment is affected by sluggishness in the Medication Management Solutions and Pharmaceutical Systems units in the United States.

Within the Diabetes Care unit, BD temporarily has paused shipments of insulin infusion sets, thanks to higher-than-anticipated rate of complaints associated with insertion during the pilot launch of the product. However, management conducted a clinical trial to gather insights and ensure that patients ultimately realize the full benefits of BD FlowSmart technology. BD continues to collaborate with Medtronic Plc (NYSE:MDT) toward full commercialization of the product

Adding to woes, the ongoing political conundrum pertaining to the repealing of Obamacare by the Republicans has given rise to uncertainties for dental stocks like BD and CONMED Corporation. Thus, lack of favorable developments in the regulatory front is a concern for these MedTech majors.

Zacks Editor-in-Chief Goes ""All In"" on This Stock

Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.

Download it free >>



Medtronic PLC (MDT): Free Stock Analysis Report

C.R. Bard, Inc. (BCR): Free Stock Analysis Report

Becton, Dickinson and Company (BDX): Free Stock Analysis Report

Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.